For years, locally advanced hepatocellular carcinoma was handed to systemic therapy almost by default — too advanced, too vascular, too complicated for the local-therapy toolbox. NRG/RTOG 1112 tested that assumption, and its results now sit in the randomized evidence base the NCCN HCC guidelines cite for SBRT. The trial: 177 eligible patients with locally advanced HCC; 74% had macrovascular invasion — the feature that historically closed every local-therapy door. SBRT (27.5–50 Gy in 5 fractions, individualized) followed by sorafenib, vs. sorafenib alone. Median overall survival: 15.8 vs. 12.3 months (adjusted HR 0.72). Median progression-free survival: 9.2 vs. 5.5 months (HR 0.55). Quality of life at 6 months: improved in 35% vs. 10%. The honest cost: grade 3+ toxicity 47% vs. 42% — real, and worth stating whenever the benefit is quoted. What I'm watching isn't just one trial. It's the convergence: radioembolization (Y-90), thermal ablation, embolization, and SBRT are increasingly sequenced and combined in liver cancer — chosen by anatomy, liver reserve, and disease pattern rather than by which clinic door the patient entered. The specialties that treat the liver are becoming colleagues with a shared toolbox. The tumor boards that still run them as rival camps are the ones behind the evidence.

The concept is elegant: image the target with a PSMA PET tracer to confirm the disease expresses the target, then swap the imaging isotope for a therapeutic one — lutetium-177 — carried by the same targeting molecule. Diagnosis and therapy, one molecular address. Watch how Pluvicto (lutetium Lu-177 vipivotide tetraxetan) has moved: 2022 — FDA approval for PSMA-positive metastatic castration-resistant prostate cancer, after ARPI therapy AND chemotherapy. March 2025 — expanded to BEFORE chemotherapy, on PSMAfore, where Pluvicto cut the risk of radiographic progression or death by 59% (HR 0.41) versus switching ARPI. 2026 — extended into hormone-sensitive metastatic disease, in combination with an ARPI (PSMAddition). Three expansions, one direction: earlier. And each one makes the selection test — PSMA PET — as consequential as the therapy itself. This is genuinely shared territory now: nuclear medicine, medical oncology, radiation oncology, and interventional radiology all touch the same patient's pathway — and the live questions (patient-specific dosimetry, sequencing radioligand therapy with SBRT and other local therapies, marrow reserve across lines of treatment) don't belong to any single specialty. Innovation with depth isn't a new molecule. It's a new map of who works together.

A 2.5 cm renal mass in a 74-year-old with cardiac history is a daily tumor-board problem, and partial nephrectomy isn't the only serious answer anymore. Two needle-and-beam disciplines now contest the same small tumors — and they win on different scorecards. Thermal ablation (cryoablation, RFA, microwave) is the IR workhorse for T1a tumors. A systematic review of nearly 5,000 patients found local control and cancer-specific survival for ablation comparable to partial nephrectomy in small masses — with fewer complications, shorter stays, and better preservation of renal function. For tumors ≤3 cm, percutaneous ablation's recurrence-free survival matches surgery in most series, and it can be repeated if a margin recurs. SBRT enters where needles struggle: hilar or central tumors near vessels and collecting system, patients who can't tolerate even a percutaneous procedure, larger T1b lesions in the truly inoperable. Modern series (I get to watch this literature as a liaison) report 2-year local control above 95% with single-fraction or 3–5 fraction regimens and low high-grade toxicity. ASTRO's model policy covers primary renal cell carcinoma SBRT for medically inoperable patients. The honest framing for the board: surgery still owns the deepest long-term data and the youngest, healthiest patients. Ablation owns small peripheral tumors in comorbid patients, with the gentlest footprint. SBRT owns the needle-hostile anatomy. Matching modality to anatomy and physiology — instead of to whoever saw the patient first — is the multidisciplinary ideal actually working.

Not long ago, metastatic cancer meant one conversation: systemic therapy, and comfort when it ran out. The oligometastatic idea — first named by Hellman and Weichselbaum in 1995 — proposed a middle state: a few deposits, not yet widespread, where local treatment might actually change the trajectory. SABR-COMET was the first randomized test: 99 patients, 2–5 lesions (the trial allowed up to 5; most had 1–3), randomized to standard care with or without comprehensive SABR to every lesion. The long-term results: 5-year overall survival 42.3% with SABR vs. 17.7% without. PFS doubled. Honesty requires the other line too: grade 3+ toxicity was higher with treatment, including 3 treatment-related deaths (4.5%). Phase 2, multi-primary, carefully selected patients — that's the fine print, and it matters. ORIOLE added biological texture: in oligometastatic prostate cancer, SABR didn't just delay progression — men whose visible lesions were all treated did better than men whose PSMA-hidden lesions were missed, suggesting total consolidation is the active ingredient, not just any ablation. ASTRO's 2022 guideline now supports definitive local therapy for oligometastatic NSCLC and prostate in the right patients. This is the revolution at work in IR and rad-onc suites every week: image-guided ablation and SBRT turning "stage IV" from a single category into a spectrum — if, and only if, the selection is honest about who's actually oligometastatic.

Surgery has a ritual so simple it almost feels too small to matter: before the first cut, everybody stops. The timeout. Names, site, side, procedure — read out loud, agreed out loud, then and only then the case starts. It exists because the alternative happened often enough to get a name: wrong-site, wrong-procedure, wrong-patient events. The Joint Commission's Universal Protocol made the pause mandatory in 2004, and OR culture absorbed it as identity, not compliance. Nobody with a CST's instincts questions the timeout. It's just what professionals do before irreversible action. Radiation oncology runs the same philosophy with different instruments. A linac timeout before beam-on. Independent physics second checks on dose calculations. Weekly chart rounds where peers review each other's plans. AAPM TG-275 built an entire report around one idea from the OR: the most powerful safety tool is a structured moment where a second mind examines the plan before the dose is delivered — and the authority to stop the line if something looks wrong. I spent 13 years in rooms where the timeout is sacred, and I work now in a field that engineered the same pause into software, checklists, and peer review. Different tools. Same culture: the plan doesn't proceed until someone has deliberately tried to find the error in it. That's not bureaucracy. That's what respect for irreversibility looks like — and both of my worlds figured it out the same way: the hard way, then on purpose.

Five treatments. No incision. Eight years of receipts. For decades, the surgery-versus-radiation conversation in localized prostate cancer ran on retrospective series and conviction. PACE-A changed the evidence base: it's the first phase 3 trial to randomize men between modern prostatectomy and five-fraction SBRT — and the 8-year results, presented at ASTRO 2026, are the ones that matter. The cancer control: 123 men, 8 UK centers, low- to favorable intermediate-risk disease; SBRT 36.25 Gy in 5 fractions; no hormone therapy in either arm. Freedom from biochemical or clinical failure at 8 years: 91% (SBRT) vs. 84% (surgery) — NOT statistically significant, and the trial was not powered to prove equivalence. Not one man in either arm died of prostate cancer. The function gap is where the trial actually speaks: urinary pad use at 5 years was 8% after SBRT vs. 48% after surgery, and median erectile-function score was 19 vs. 5 on a 25-point scale. As PI Nicholas van As put it, patients previously had to choose "without randomized evidence directly comparing the treatments. PACE-A changes that." When cancer control is this close and mortality this low, the decision doesn't belong to the survival curves — it belongs to the patient's priorities: continence, sexual function, treatment burden. Our job is to present both columns honestly, including the statistical tie at the top.

They treated every metastasis they could see. It didn't matter. NRG-BR002 just delivered one of the most sobering results in recent radiation oncology: in oligometastatic breast cancer, ablating every visible metastasis with SBRT or surgery — on top of first-line systemic therapy — did NOT improve progression-free or overall survival. The numbers: • 125 patients, 4 or fewer metastatic lesions, 47 institutions across the US and Canada • Median PFS: 23 months (systemic therapy alone) vs. 19.5 months (systemic + ablation of all known sites) • Overall survival: no significant difference • Longer follow-up: still no PFS benefit, no reduction in new metastases elsewhere Read that again. Treating all visible disease didn't stop new disease from appearing elsewhere. The visible tumors were never the whole story — they were the visible part of a systemic disease behaving systemically. This is the trial that should retire a reflex: "there's a spot, let's zap it." Local control is real. But local control is not systemic control, and conflating the two is how patients get toxicity without benefit. The carousel breaks down the trial design and what it actually proved. Swipe through. When the imaging shows you a target but the biology says otherwise — which one do you treat? #RadOnc #SBRT #ClinicalTrials #IR #InterventionalRadiology

In surgery, nobody trusts their memory. That's the whole point of the count. Every sponge, every needle, every instrument — counted in, counted out, reconciled before closure. Not because the team is careless. Because the team knows memory is the least reliable safety system ever designed. Radiation oncology has its own version of this discipline, and the best departments treat it the same way: independent plan checks, timeout verifications, daily image guidance. But here's what the OR gets right that too many clinics still treat as optional — the count is a CULTURE, not a checklist. A checklist can be pencil-whipped. A culture can't. In the OR, the circulator who stops the surgeon to reconcile a count isn't being difficult — they're being the system working as designed. The hierarchy flattens for the count. Rank doesn't outrank the sponge. Translate that to the linac: does your department's second checker have real authority to stop a plan? Or is the "independent check" a signature from someone who already knows what the first checker found? The principle travels cleanly across modalities: build the verification into the culture, give the verifier real power, and never trust memory where you can count instead. What does the "count" look like in your department? #RadOnc #PatientSafety #QualityAssurance #IR #InterventionalRadiology

Myth: irradiating a bigger area cures more cancer. For years, the logic felt airtight in high-risk prostate cancer: if microscopic disease hides in the pelvic lymph nodes, then whole-pelvic radiotherapy should beat prostate-only radiotherapy. Bigger field, more cancer killed, better survival. Intuition says yes. Five randomized trials and 5,172 patients say no. A new systematic review and meta-analysis pooled every phase 3 trial comparing whole-pelvic RT against prostate-only RT in clinically node-negative high-risk localized prostate cancer — RTOG 9413, GETUG-01, POP-RT, PEACE-2, and RTOG 0924: • Overall survival: NO improvement with whole-pelvic RT • The apparent benefits in biochemical and metastasis-free survival? Driven ENTIRELY by a single single-center trial. Exclude it, and the benefit vanishes. That last detail is the whole lesson. One outlier trial carried the entire narrative for years. Strip it out and the emperor has no field size. This doesn't mean pelvic nodal irradiation never helps anyone — but it does mean "bigger is better" was never evidence. It was geometry masquerading as oncology. The carousel walks through the five trials and where the signal actually came from. Swipe through. What other "obvious" oncology intuitions are waiting for their meta-analysis? #RadOnc #ProstateCancer #EvidenceBasedMedicine #IR #InterventionalRadiology

If your KOL meeting could have been an email, you weren't doing field medical. Controversial? Maybe. But here's the uncomfortable truth about scientific exchange: most of what passes for it is one-directional. A deck, a monologue, a "great discussion" that was really a presentation with questions at the end. Real field-medical work looks nothing like that: • The best insight of the meeting usually comes AFTER you close the laptop. The deck gets you in the room; the conversation after it is the actual job. • If you talked more than you listened, you failed — regardless of how good the slides were. Insights don't live in presentations. They live in the unguarded sentence a KOL says when they think the formal part is over. • A KOL who corrects you just gave you more value than one who agrees with you. Disagreement is data. Agreement is pleasant and useless. • The write-up matters more than the visit. An insight that isn't documented, contextualized, and routed to the right team within 24 hours didn't happen — it was a nice conversation. The deck is the least interesting thing in the room. It's the price of admission, not the product. Medical Affairs isn't measured in meetings held. It's measured in what the organization learned because you were in those rooms. What's the most valuable thing a KOL ever told you AFTER the slides were put away? #MedicalAffairs #FieldMedical #IR #InterventionalRadiology

Radiation therapy for... knee arthritis? Stay with me. At ASTRO 2026, researchers presented an integrated analysis of a completed randomized trial testing LOW-DOSE radiotherapy for early knee osteoarthritis — and the numbers demand attention: • 292 patients with symptomatic early knee OA, randomized to standard drugs alone vs. drugs + orthovoltage LDRT (4.5 Gy in 10 fractions) • Greater, more durable improvements in pain, physical function, and quality of life with LDRT • Less structural progression on MRI at 12 and 36 months — less cartilage deterioration, less bone marrow edema • Disability risk cut by two-thirds (adjusted HR 0.33); total knee replacements cut nearly in half (HR 0.51) • Biggest benefit in KL grade 2 disease: disability HR 0.37, knee replacement HR 0.32 Now the honest caveats, because this is how the field should talk about early data: • This is one integrated analysis from a Russian center (Northern State Medical University). It needs independent replication before anyone changes practice. • The mechanism — anti-inflammatory effect of low-dose radiation — is plausible but not proven here. • 4.5 Gy is a fraction of cancer-treatment doses, but "low dose" still means ionizing radiation for a non-malignant condition. The risk-benefit bar is, correctly, very high. Still: if treating inflammation early can change the course of a disease that ends in joint replacement, that's worth chasing — carefully. Where else is low-dose radiation being under-explored? #RadOnc #ASTRO26 #Osteoarthritis #IR #InterventionalRadiology

After brain metastasis surgery, one big radiation dose was the standard. As of ASTRO 2026, it shouldn't be. Alliance A071801 — the FIRST randomized phase 3 trial comparing single-fraction vs. fractionated stereotactic radiosurgery after resection of a large brain metastasis — just rewrote the postoperative playbook: • 242 patients, resected brain met > 2 cm (melanoma, lung, breast primaries most common) • 1-year surgical bed control: 87% (3–5 fractions) vs. 81% (single fraction) • Median overall survival: 29 months vs. 20 months — NINE months longer with fractionation • Side effects: no significant difference (radiation necrosis 14% vs. 10%, cerebral edema 8% vs. 9%) The survival difference caught even the investigators off guard — deaths were from systemic disease, not brain mets. As PI Paul Brown (Mayo Clinic) put it: "Something with brain control affects survival. We don't know quite what." What changes Monday morning: for resected large brain metastases, 3–5 fraction SRS should now be the default conversation, not the exception. As co-author Ayal Aizer (Dana-Farber) said, this moves fractionated SRS "from a reasonable practice supported by retrospective data to one backed by a randomised phase 3 trial." Better control. Longer survival. Same safety. That's not incremental — that's a new standard. Is your center's postoperative SRS protocol already there? #RadOnc #ASTRO26 #BrainMets #Neurosurgery #IR #InterventionalRadiology